Back to top

crispr: Archive

Zacks Equity Research

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.

AZNPositive Net Change BAYRYPositive Net Change EDITPositive Net Change ALLOPositive Net Change

Zacks Equity Research

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.

ANIPPositive Net Change CTMXNegative Net Change ALLOPositive Net Change ETNBPositive Net Change